» Articles » PMID: 19381015

Consuming Fructose-sweetened, Not Glucose-sweetened, Beverages Increases Visceral Adiposity and Lipids and Decreases Insulin Sensitivity in Overweight/obese Humans

Abstract

Studies in animals have documented that, compared with glucose, dietary fructose induces dyslipidemia and insulin resistance. To assess the relative effects of these dietary sugars during sustained consumption in humans, overweight and obese subjects consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 weeks. Although both groups exhibited similar weight gain during the intervention, visceral adipose volume was significantly increased only in subjects consuming fructose. Fasting plasma triglyceride concentrations increased by approximately 10% during 10 weeks of glucose consumption but not after fructose consumption. In contrast, hepatic de novo lipogenesis (DNL) and the 23-hour postprandial triglyceride AUC were increased specifically during fructose consumption. Similarly, markers of altered lipid metabolism and lipoprotein remodeling, including fasting apoB, LDL, small dense LDL, oxidized LDL, and postprandial concentrations of remnant-like particle-triglyceride and -cholesterol significantly increased during fructose but not glucose consumption. In addition, fasting plasma glucose and insulin levels increased and insulin sensitivity decreased in subjects consuming fructose but not in those consuming glucose. These data suggest that dietary fructose specifically increases DNL, promotes dyslipidemia, decreases insulin sensitivity, and increases visceral adiposity in overweight/obese adults.

Citing Articles

Probiotic Kefir Improves Renal Disorders in Ovariectomized Female SHR with High Fructose Intake-Induced Metabolic Syndrome.

da Silva Escouto L, Batista T, Peixoto P, Firmino F, Ronchi S, de Souza Barroso M Probiotics Antimicrob Proteins. 2025; .

PMID: 40080096 DOI: 10.1007/s12602-025-10490-w.


Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet.

Arivazhagan L, Delbare S, Wilson R, Manigrasso M, Zhou B, Ruiz H JHEP Rep. 2025; 7(2):101222.

PMID: 39911943 PMC: 11795143. DOI: 10.1016/j.jhepr.2024.101222.


Examining Prenylated Xanthones as Potential Inhibitors Against Ketohexokinase C Isoform for the Treatment of Fructose-Driven Metabolic Disorders: An Integrated Computational Approach.

Elsaman T, Mohamed M Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861187 PMC: 11768319. DOI: 10.3390/ph18010126.


Targeting ultra-processed foods for prevention of type 2 diabetes: state of the evidence and future directions.

Mendoza K, Barquera S, Tobias D Diabetologia. 2025; 68(3):495-506.

PMID: 39825911 DOI: 10.1007/s00125-025-06358-x.


Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.

Hirano T J Diabetes Investig. 2025; 16(3):370-383.

PMID: 39778086 PMC: 11871407. DOI: 10.1111/jdi.14398.


References
1.
Okada M, Matsui H, Ito Y, Fujiwara A, Inano K . Low-density lipoprotein cholesterol can be chemically measured: a new superior method. J Lab Clin Med. 1998; 132(3):195-201. DOI: 10.1016/s0022-2143(98)90168-8. View

2.
Marcovina S, Packard C . Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med. 2006; 259(5):437-46. DOI: 10.1111/j.1365-2796.2006.01648.x. View

3.
Hyson D, Rutledge J, Berglund L . Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep. 2003; 5(6):437-44. DOI: 10.1007/s11883-003-0033-y. View

4.
Genuth S, Alberti K, Bennett P, Buse J, DeFronzo R, Kahn R . Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11):3160-7. DOI: 10.2337/diacare.26.11.3160. View

5.
Koivisto V, Yki-Jarvinen H . Fructose and insulin sensitivity in patients with type 2 diabetes. J Intern Med. 1993; 233(2):145-53. DOI: 10.1111/j.1365-2796.1993.tb00667.x. View